Evista (chemical name: raloxifene) is a SERM approved by the U.S. Food and Drug Administration (FDA) to: 1  reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who haven't been diagnosed but are at higher-than-average risk for disease.
Types of paper ICT Express publishes original research papers in English in the fields of ICT convergence, platform technologies, communication networks, and device technologies. ICT Express accepts short-length (up to 4 pages in double columns and additional 2 pages will be allowed with over page charge (100USD/1page)) high-quality, original articles in Latex or Word format. Sample manuscript can be downloaded here.
The most frequent publishing delay is 6 months â these are patents that were filed 12 months after the priority date. The 18-month spike is the case where the priority date is the same as the filing date for a new application, and the vanilla 18-month rule applies.